Despite significant advances in the treatment of acne, the problem associated with therapy improvement still remains very important. Retinoids are currently the first-choice drugs. Since side effects of isotretinoin are dose-related, it is very important to search for techniques that would reduce the daily and course doses and increase the compliance in acne patients. Objectives. To do the retrospective analysis of out-patients medical records and frequency of patients' visits according to the sex, age and clinical variant of disease; to study the effectiveness of treatment with low doses of isotretinoin (Acnecutan) in patients with mild and moderate acne. Material and Methods. A retrospective analysis of 20,584 patients who had made an outpatient visit to a dermatologist in Moscow medical institutions within 10 years (2003-2012). Treatment with low-and standard-dose isotretinoin was conducted in 98 acne patients. Low doses (less than 0.2-0.4 mg/kg body weight) of the drug were prescribed for 4-7 months to be taken after the evening meal to patients with mild and moderate acne, while the doses of 0.4-0.6 mg/kg body weight were prescribed to patients with severe acne (as recommended by the manufacturer). When determining the daily dose, allowance was made for the clinical form, severity, location, prevalence of the process, and the individual response of patients to treatment. The follow-up was 68 months. Results. The effectiveness of treatment with isotretinoin was observed in 100% of cases. Under overall evaluation of the dynamics of inflammatory elements in patients with mild severity, papules and pustules resolved by the end of the 1st month of treatment, while in 70% of patients with moderate severity - in the end of the 3rd or 4th month. Clinical recovery and resolution of inflammatory acne elements in patients with acne vulgaris of moderate severity were achieved after Acnecutan therapy for 3 months. Side effects of various severity caused by retinoids were observed in all patients who rreceived Acnecutan. A significantly smaller number of side effects was observed in patients with mild to moderate severity when low-dose administration of isotretinoin was employed. According to the long-term results of treatment (6 months) in patients who received isotretinoin monotherapy, clinical improvement was achieved in 92.8% of cases. Conclusions. The results of the clinical use of isotretinoin (Acnecutan) indicate a high level of safety and tolerability. Therapy with low-dose isotretinoin is effective and pathogenetically justified for treating patients with acne vulgaris and late-onset acne of mild to moderate severity.